Sort
40,608 grants matching “prostate cancer”
Cancer Therapy Clinical Trials Using Novel Recombinant Vaccines
$853,223James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
Clinical trials employing cancer vaccine combination therapies
$853,223James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
FUSION GENES PREDICT PROSTATE CANCER RECURRENCE
$853,200The Leland Stanford Junior University · · FY2016 · Department of the Army
LASER CELL PROCESSING FOR BASIC AND CLINICAL RESEARCH
$853,134Cyntellect, Inc. · R44 · FY2000 · RR
P3IK Signaling and Biology of Therapeutic Response in Brain and Prostate Tumors
$853,099Eric C Holland · Sloan-Kettering Inst Can Research · U01 · FY2010 · CA
Commercialization of a proprietary Ga-68 PSMA-targeted drug for PET imaging in recurrent prostate cancer
$853,093David Alexoff · Five Eleven Pharma, Inc. · R44 · FY2019 · CA
PROSTATE CANCER ANTIGEN PRESENTATION BY HLA-E AS A NEW TARGET MECHANISM FOR IMMUNOTHERAPY
$853,041Oregon Health & Science University · · FY2019 · Department of the Army
Human Immune Responses to Tumor Antigens for Cancer Vaccine Development
$852,537Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Appraisal and Diagnostic Delay in Colon Cancer
$852,467Laura A Siminoff · Virginia Commonwealth University · R01 · FY2010 · CA
Illinois Oncology Research Association Community Clinical Oncology Program
$852,293Nguyet A. Le-Lindqwister · Oncology-Hematology Assoc-Central Ill · U10 · FY2013 · CA
Opaganib as a Medical Countermeasure for Gastrointestinal Acute Radiation Syndrome
$852,174Charles D Smith · Apogee Biotechnology Corporation · R44 · FY2023 · AI
REPURPOSING THYMOQUINONE AS THERAPY FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
$852,000The Morehouse School Of Medicine, Inc. · · FY2018 · Department of the Army
2/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership
$851,603Clayton Yates · Tuskegee University · U54 · FY2020 · CA
LOSS OF ZDHHC-MEDIATED SCRIBBLE PALMITOYLATION DISRUPTS CELL POLARITY AND PROMOTES PROSTATE CANCER PROGRESSION
$851,580The General Hospital Corporation · · FY2017 · Department of the Army
Effect of methodological and biological variability on molecular profiling of extracellular vesicles in cancer detection
$851,560Alexander R. Ivanov · Northeastern University · R01 · FY2019 · CA
TRANSCRIPTIONAL REPROGRAMMING OF LETHAL SMALL CELL PROSTATE CANCER.
$851,534Duke University · · FY2021 · Defense Health Agency
Center for Allaying Health Disparities Through Research and Education (CADRE)
$851,512John W Garland · Central State Univ (Wilberforce, Oh) · P20 · FY2009 · MD
Abiraterone Acetate in Childen with Classic 21-Hydroxylase Deficiency
$850,622Perrin C White · Ut Southwestern Medical Center · U01 · FY2018 · HD
Abiraterone Acetate in Childen with Classic 21-Hydroxylase Deficiency
$850,621Perrin C White · Ut Southwestern Medical Center · U01 · FY2019 · HD
Basic Research Support for the CCR
$850,265Robert Wiltrout · Division Of Basic Sciences - Nci · ZIC · FY2013 · CA
Prostate Cancer in a Black Population
$850,246McRistina Leske · State University New York Stony Brook · R01 · FY2007 · CA
Liver Cancer Disparities in Alaska Native and American Indian People
$850,177George Ioannou · University Of Washington · P20 · FY2022 · CA
Application of RiboTag-seq to Exploration of Tumor Microenvironments
$850,000David R Morris · University Of Washington · RC2 · FY2009 · CA
The VITamin D and OmegA-3 TriaL (VITAL): Post-Intervention Follow-Up
$850,000Joann Elisabeth Manson · Brigham And Women'S Hospital · R01 · FY2022 · AT
DCP - COPTRG - SELECT/PCPT
$850,000David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2014 · CA